Star Therapeutics is a clinical stage therapeutics company developing therapies for rare diseases.

Star Therapeutics was founded and is led by an experienced team of drug hunters with expertise and multiple exits in the hematology and autoimmune space. Star Therapeutics' lead program is a novel biologic against a common form of hemophilia, Von Willebrand disease, that lacks a convenient and effective prophylactic treatment option. The company’s additional programs aimed at pursuing unaddressed targets in the complement pathway, a central pillar of the innate immune system and driver of several autoimmune diseases.